Hikma Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Hikma Pharmaceuticals generated cash of $608,000,000, which is more than the previous year. Cash used in financing activities reached the amount of -$337,000,000 last year. Net change in cash is therefore -$65,000,000.
Cash Flow
| 2014 | 425M | -342M | 30M |
|---|---|---|---|
| 2015 | 366M | -162M | 77M |
| 2016 | 293M | -695M | 19M |
| 2017 | 443M | -151M | -220M |
| 2018 | 430M | -96M | -278M |
| 2019 | 472M | -151M | -155M |
| 2020 | 464M | -283M | -298M |
| 2021 | 638M | -238M | -287M |
| 2022 | 530M | -607M | -58M |
| 2023 | 608M | -333M | -337M |
HKMPY Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 270M | 426M | 323M | 442M | 276M | 227M | 155M | 553M | 280M | 168M |
Operating activities | ||||||||||
Net income | 281M | 233M | 544M | 558M | 491M | 293M | -738M | 210M | 318M | 362M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 198M | 193M | 145M | 91M | 99M | 121M | 1.24B | 146M | 73M | 72M |
Stock-based compensation expense | 25M | 22M | 29M | 27M | 24M | 21M | 22M | 22M | 15M | 8M |
| Deferred income tax benefit | 25M | 22M | 29M | 27M | 24M | 21M | 22M | 22M | 15M | 8M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -24M | 4M | -166M | -47M | 21M | -41M | 52M | -128M | -78M | -16M |
Inventories | -115M | -102M | 38M | -180M | -25M | -51M | -31M | -32M | 4M | 2M |
Accounts payable | 88M | 16M | 14M | 6M | -6M | 88M | 15M | 46M | 28M | 16M |
Cash generated by operating activities | 608M | 530M | 638M | 464M | 472M | 430M | 443M | 293M | 366M | 425M |
Investing activities | ||||||||||
Purchases Of Investments | -27M | -15M | -3M | -5M | -6M | -4M | -10M | -17M | -21M | -5M |
Investments In Property Plant And Equipment | -169M | -225M | -229M | -224M | -186M | -139M | -151M | -190M | -137M | -118M |
Acquisitions Net | -105M | -380M | -17M | -60M | 19M | 27M | 5M | -515M | 31M | -225M |
Cash generated by investing activities | -333M | -607M | -238M | -283M | -151M | -96M | -151M | -695M | -162M | -342M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 1.92B | 0 | 0 | 0 | 0 | 1M | 0 |
Payments for dividends | -137M | -125M | -120M | -109M | -97M | -84M | -79M | -77M | -64M | -55M |
Repurchases of common stock | 0 | -300M | 0 | -375M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -93M | 456M | -476M | -1.73B | 2M | -372M | -78M | -663M | 168M | -121M |
Cash used in financing activities | -337M | -58M | -287M | -298M | -155M | -278M | -220M | 19M | 77M | 30M |
Net Change In Cash | -65M | -156M | 103M | -119M | 166M | 49M | 72M | -398M | 273M | 112M |
Cash at end of period | 205M | 270M | 426M | 323M | 442M | 276M | 227M | 155M | 553M | 280M |